Search PubMed⌕ Search

Biomedical subjects

K Hayduk

Publications and source records attributed to K Hayduk.

At least 19 recordsLinked to original sources
PubMed1992

[Fatal pulmonary embolism after lysis therapy in post-traumatic renal vein thrombosis].

A 30-year-old man was hospitalized because of increasing dyspnoea for 4 weeks. Chest X-ray demonstrated an infiltrate in the right upper lobe and enlargement of the central pulmonary arteries. Lung perfusion scintigraphy revealed, typical of embolism, absent perfusion of the entire right upper lobe, as well as segmental embolism in the left upper and basal lobes. Phlebography of the legs and pelvis was unremarkable. Intravenous heparin treatment was begun (initially 1,250 IU/h, then dosage adjusted according to the partial thromboplastin time). Nonetheless the patient's condition deteriorated the next day and the respiratory failure increased (pO2 61 mm Hg despite oxygen supply). Streptokinase was then infused in ultra-high dosage, 9 million units over 6 hours. But the patient died of cardiocirculatory failure 4 hours after the streptokinase infusion had been finished. Autopsy revealed fulminant recurrent pulmonary embolism with occlusion of the right main pulmonary artery. The emboli had their origin in renal vein thrombosis extending into the inferior vena cava, which had probably been caused by slight trauma to the flank during a game of squash 6 weeks previously.

Adult↗
PubMed1989

[Fine needle puncture cytology in metastatic hepatocellular carcinoma].

Distant metastases occur in 50% of cases of HCC. Bones are involved in 11% with the spine as the most important localization. In the reported case a tumorous mass in the liver, suspicious for HCC according to clinical and cytological criteria, was proved to be malignant by the cytologic examination of a metastasis to the sacrum.

Aged↗
PubMed1987

Efficacy and safety of doxazosin in hypertension therapy.

In double-blind, controlled, parallel, comparative trials, the blood pressure-lowering effect of doxazosin was compared with that of placebo and other active agents. In 1 large, multicenter study, 903 patients were evaluated: 408 patients received doxazosin; 323, active comparative agents (nadolol, metoprolol, prazosin or hydrochlorothiazide); and 172, placebo. In another smaller study doxazosin was compared with terazosin treatment. Doxazosin administered as monotherapy lowered blood pressure significantly when compared with baseline and the placebo-treated group. Doxazosin therapy resulted in substantial reductions from baseline readings for systolic and diastolic blood pressure in both the standing and supine positions; the effect of doxazosin was similar to that of the comparative drugs; however, unlike beta blockers, no significant change in heart rate was demonstrated. The effectiveness and safety of doxazosin are practically identical in young and elderly patients, as well as in blacks and whites. Doxazosin exhibited a favorable lipid profile and the reported side effects of doxazosin were comparable to those observed with placebo and other study drugs. Another multicenter trial reported that doxazosin therapy was effective at low doses; 76% of those responders achieved controlled blood pressure at a mean dosage of 3.3 mg daily.

Adrenergic beta-Antagonists↗
PubMed1987

Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.

A multicenter, double-blind study compared the antihypertensive efficacy and safety of doxazosin and terazosin as once-daily therapy. Doxazosin, a potent antihypertensive agent, selectively inhibits alpha 1 adrenoceptors. Its pharmacokinetic profile, including gradual onset of action, long plasma elimination half-life and long duration of action, permits once-daily dosing. Terazosin, a structural analog of prazosin, also inhibits alpha 1 adrenoceptors and is recommended as once or twice-daily therapy. Nineteen (73%) of 26 patients randomly assigned to receive doxazosin were therapeutic successes; 17 (65%) achieved normalized blood pressure (defined as blood pressure less than or equal to 90 mm Hg). The mean final daily dosage in patients classified as therapeutic successes was 2.4 mg. Eighteen (64%) of 28 terazosin-treated patients were considered therapeutic successes; 16 (57%) achieved normalized blood pressure. The mean final daily dosage in patients classified as therapeutic successes was 5.6 mg. Treatment-related side effects were observed in 30% of doxazosin-treated and 39% of terazosin-treated patients. Most side effects observed in either treatment group were mild or moderate and either disappeared or were tolerated with continued therapy. Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage.

Adrenergic alpha-Antagonists↗
PubMed1979

Regulation of aldosterone secretion in dehydrated babies.

The factors controlling aldosterone secretion were measured in 12 patients with moderate to severe dehydration during the first year of life. Secondary hyperaldosteronism was present in all cases (mean plasma aldosterone concentration 414.6 ng/dl), as well as increased plasma cortisol levels (mean 49.7 microgram/dl). Plasma cortisol, an indirect parameter of stimulation of the adrenal cortex by ACTH, showed the highest correlation with plasma aldosterone (r = 0.82). Despite a mean elevation of 168 ng AT/ml/h the plasma renin concentration did not seem to play the dominant role in the regulation of aldosterone secretion in these infants. High serum sodium concentrations have a clearly inhibiting effect on aldosterone secretion as shown by the negative correlation coefficient of r = 0.80.

Aldosterone↗
PubMed1978

[Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].

In 34 patients saralasin was infused after variable degrees of sodium depletion in order to differentiate between essential and renin-induced hypertension. After sodium-depletion of short duration mean arterial pressure dropped more than 10 mm Hg in 9 of 25 patients with essential and in 7 of 9 patients with renin-induced hypertension. After long-lasting sodium depletion the fall of mean arterial pressure exceeded 10 mm Hg in 11 of 16 patients with essential and in 8 of 9 patients with renin-induced hypertension. Thus saralasin did not discriminate essential and renin-induced hypertension. Also, plasma renin concentration before and after saralasin did not allow to differentiate between the two forms of hypertension. The changes of renin during infusion of saralasin was negatively correlated to the change of blood pressure. Renal vein renin ratio in patients with renovascular hypertension was not modified by saralasin. Renin and aldosterone changed inversely during saralasin infusion.

Aldosterone↗
PubMed1978

[Side-effects on longterm treatment with antihypertensives (author's transl)].

Unspecific complaints as a result of lowering the blood pressure and substance-specific side-effects may occur during antihypertensive therapy. The frequency of the side-effects depends on the substance used (10 to 50%) and on the dose. An individual therapy, which in most cases involves the use of several substances, can reduce the frequency of side-effects decisively. With optimal therapy the ratio of benefits (= prevention of cardiovascular diseases) to side-effects (= sum of undesirable reactions) is completely acceptable in the treatment of high blood pressure.

Age Factors↗
PubMed1977

[Hemodynamic changes after angiotensin II blockade by saralasin (author's transl)].

Saralasin, an angiotensin II inhibitor was infused in 10 hypertensive patients. A blood pressure reduction was achieved after stimulation of the renin-angiotensin-system by salt depletion. Heart rate and cardiac output failed to compensate for reduction of blood pressure. Thus circulatory reflex-mechanisms are inhibited by saralasin. A direct influence on baroreceptor mechanism and/or catecholamines is probable. Failure of the hypotensive effect of saralasin in salt-depleted patients after administration of beta-blockers supports this hypothesis.

Adrenergic beta-Antagonists↗